StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
MNPRMonopar Therapeutics
stockpulse.co.kr
Nasdaq
$71.95▲ 1.80%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $482.0MShares out 6.7M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

26
  • 4d agoAfter-hours26.10.21 05:59
    4Ownership#●●●

    Monopar Therapeutics

    Insider Chandler Robinson of Monopar Therapeutics reported a change in beneficial ownership of securities on October 20, 2026. This filing serves as a standard Form 4 disclosure regarding insider holdings.…more

    $71.95+1.80%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.5After-hours26.10.06 06:43
    4Ownership

    Monopar Therapeutics

    Christopher M. Starr of Monopar Therapeutics reported a change in beneficial ownership of securities effective October 1, 2026. This filing is a standard Form 4 disclosure regarding executive stock holdings.…more

    $71.95+1.80%vs prev close
    View filingShare
  • 10.2After-hours26.10.03 07:15
    4Ownership

    Monopar Therapeutics

    Insider Andrew Cittadine of Monopar Therapeutics reported a change in his beneficial ownership of securities as of September 30, 2026. This filing is a standard Form 4 statement regarding insider share activity.…more

    $71.95+1.80%vs prev close
    View filingShare

25 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 8.19Pre-market26.08.19 21:00
    #●●●#●●●#●●●

    Monopar Appoints New Medical Affairs EVP and Announces Upcoming AASLD Presentations…more

    Monopar Therapeutics has appointed Dr. Jeffrey D. Kent as Executive Vice President of Medical Affairs to lead preparations for the potential FDA approval of its Wilson disease candidate, ALXN1840. The company also announced that it will present new clinical data for the drug at the AASLD Liver Meeting in November 2026.…more

    $71.95+1.80%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 8.12Regular26.08.12 22:30

    ●●●●●●●● ●●●●● ●●●●●●

    Monopar Therapeutics has begun the rolling submission of a New Drug Application to the FDA for its Wilson disease treatment, ALXN1840. The company maintains sufficient capital to fund operations through the end of 2027 while advancing its commercialization strategy.…more

    $71.95+1.80%vs prev close
    Read sourceShareGlobeNewswire
  • 7.22Pre-market26.07.22 21:00

    ●●●●●●●● ●●●●● ●●●●●●

    모노파 테라퓨틱스가 윌슨병 치료제 'ALXN1840'에 대한 신약 허가 신청(NDA) 제출을 미국 FDA에 시작했습니다. 이번 NDA 제출은 획기적인 신약 승인 가능성을 높이며, 윌슨병 환자들에게 새로운 치료 옵션을 제공할 것으로 기대됩니다.…more

    $71.95+1.80%vs prev close
    Read sourceShareGlobeNewswire

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →